We are live on ! Find out more

TransCode Therapeutics

RNAZ

Market cap $27.9M

1.65 USD

-0.07

4.07%

At close Updated Sep 18, 4:00 PM EDT

Pre-market

After hours

1.69

+0.04

2.42%

1 day

-4.07%

5 days

0%

1 month

-49.07%

3 months

-64.89%

6 months

-82.72%

Year to date

-77.7%

1 year

-85.31%

5 years

-100%

10 years

-100%

About: TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.

Employees: 12

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 100%

Negative 0%

TransCode Therapeutics, Inc. (RNAZ) Discusses Advancing Multi-Platform Oncology Pipeline Targeting Metastatic Cancer Transcript

TransCode Therapeutics, Inc. (RNAZ) Discusses Advancing Multi-Platform Oncology Pipeline Targeting Metastatic Cancer Transcript

TransCode Therapeutics, Inc. (RNAZ) Discusses Advancing Multi-Platform Oncology Pipeline Targeting Metastatic Cancer Transcript

TransCode Therapeutics Announces Leadership Transition

Tom Fitzgerald, Chief Financial Officer, Announces his Retirement John Tattory, to become Interim Chief Financial Officer BOSTON, Sept. 10, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, today announced the retirement of its Chief Financial Officer, Tom Fitzgerald.

TransCode Therapeutics Announces Leadership Transition

TransCode Therapeutics Announces Publication Demonstrating Survival Benefit of TTX-MC138 in Preclinical Model of Breast Cancer Bone Metastasis

Published study in Cancers highlights therapeutic potential of targeting microRNA-10b in bone metastasis with TransCode's lead therapeutic candidate BOSTON, Aug. 31, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA-based therapeutics for the treatment of high risk and advanced cancers, today announced the publication of a peer-reviewed article in Cancers titled, "Targeting miR-10b in Breast Cancer Bone Colonization Model Using Image-Guided Nucleic Acid-Based Therapeutics." The study reports that TransCode's lead therapeutic candidate, TTX-MC138, produced significant survival benefits in a preclinical model of breast cancer bone metastasis while demonstrating favorable tolerability and no observed systemic toxicity.

TransCode Therapeutics Announces Publication Demonstrating Survival Benefit of TTX-MC138 in Preclinical Model of Breast Cancer Bone Metastasis

TransCode Therapeutics, Inc. (RNAZ) Discusses Strategic, Scientific, and Clinical Updates With Focus on TTX-MC138 Phase 2a Trial in Colorectal Cancer Prepared Remarks Transcript

TransCode Therapeutics, Inc. (RNAZ) Discusses Strategic, Scientific, and Clinical Updates With Focus on TTX-MC138 Phase 2a Trial in Colorectal Cancer Prepared Remarks Transcript

TransCode Therapeutics, Inc. (RNAZ) Discusses Strategic, Scientific, and Clinical Updates With Focus on TTX-MC138 Phase 2a Trial in Colorectal Cancer Prepared Remarks Transcript

TransCode Therapeutics to Host R&D Webcast on June 18, 2026

Live Webcast to Highlight TTX-MC138 Phase 2a Trial, Three-Platform Pipeline, and Investment Thesis BOSTON, June 8, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical-stage oncology company advancing a three-platform pipeline in RNA therapeutics and immuno-oncology, today announced it will host its first live virtual R&D Webcast on Thursday, June 18, 2026, at 10:00 a.m. Eastern Time.

TransCode Therapeutics to Host R&D Webcast on June 18, 2026

TransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic Cancer

TransCode reports no dose-limiting toxicities, durable disease stabilization in metastatic patients; advances to Phase 2 development in ctDNA-positive cancers using next-generation RNA therapeutics. BOSTON, June 3, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, today announced further results of the Phase 1a dose escalation clinical trial.

TransCode Therapeutics Successfully Completes Phase 1a Clinical Trial, Reports Safety and Stabilization Data for TTX-MC138 in Metastatic Cancer

TransCode Therapeutics Initiates Phase 2a Clinical Trial with TTX-MC138 in Patients with ctDNA Positive Colorectal Cancer

BOSTON, May 27, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, today announced the initiation of its Phase 2a clinical trial. The study is to evaluate TransCode's lead therapeutic candidate, TTX‑MC138, in patients with circulating tumor DNA (ctDNA) positive colorectal cancer following curative‑intent therapy.

TransCode Therapeutics Initiates Phase 2a Clinical Trial with TTX-MC138 in Patients with ctDNA Positive Colorectal Cancer

TransCode Therapeutics Appoints Dr. Anna Moore as Chair of Scientific Advisory Board; Announces Sponsored Research Agreement with Michigan State University

BOSTON, April 27, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering RNA and immuno-oncology therapeutics for the treatment of high risk and advanced cancers, today announced the appointment of Anna Moore, PhD, as Chair of its Scientific Advisory Board and the signing of a sponsored research agreement (SRA) with Michigan State University (MSU). Dr. Moore, Associate Dean for Research Development, Director of the Precision Health Program and Professor in the Departments of Radiology and Physiology at Michigan State University, is a co-founder of TransCode Therapeutics and globally recognized expert in molecular imaging and RNA-targeted cancer therapeutics.

TransCode Therapeutics Appoints Dr. Anna Moore as Chair of Scientific Advisory Board; Announces Sponsored Research Agreement with Michigan State University

TransCode Therapeutics Enters into Agreements for up to $20 Million Flexible Financing, Extending Company's Runway into Late 2027/Early 2028

BOSTON, April 7, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ, the "Company"), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, today announced that it has entered into an agreement with an institutional healthcare investor for financing of up to $20 million. The arrangement comprises pre-paid advances of up to $6 million and a three-year Standby Equity Purchase Agreement (SEPA) providing the Company the right to sell up to $14 million of its common stock to the investor, subject to certain conditions.

TransCode Therapeutics Enters into Agreements for up to $20 Million Flexible Financing, Extending Company's Runway into Late 2027/Early 2028

TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer Patients

TransCode adds a unique adenovirus technology platform to its early-stage pipeline that has the potential to address a difficult to treat disease such as muscle-invasive bladder cancer. BOSTON, March 3, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, today announced that it has entered into an exclusive, worldwide, fully paid-up royalty-free license agreement with Unleash Immuno Oncolytics, Inc. ("Unleash").

TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer Patients

See News Rankings

Price charts implemented using Lightweight Charts™